Teva and Alvotech Celebrate FDA Approval for SELARSDI™
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), in collaboration with Alvotech, has achieved a remarkable milestone. The U.S. Food and Drug Administration (FDA) has granted approval for SELARSDI™ (ustekinumab-aekn), designating it as interchangeable with the reference biologic, Stelara® (ustekinumab). This approval signifies a leap forward in enhancing patient access to effective treatment options in the field of immunology.
Understanding SELARSDI™ Approval
As of the approval date, SELARSDI is authorized for all presentations that align with those of the reference product, which includes its administration for treating various conditions. SELARSDI is specifically indicated for moderate to severe plaque psoriasis, active psoriatic arthritis in both adults and pediatric patients aged six and older, as well as Crohn’s disease and ulcerative colitis in adults.
Significance of Interchangeability
The FDA’s declaration of SELARSDI as interchangeable is a significant development in the biosimilar marketplace. According to Thomas Rainey, Senior Vice President, U.S. Biosimilars at Teva, this approval is essential for patients and healthcare providers. It will not only broaden the accessibility of this crucial treatment but may also contribute to a reduction in healthcare costs by providing more affordable options.
Expanding Treatment Options for Patients
This innovative treatment, SELARSDI, utilizes a human monoclonal antibody format, which selectively targets interleukin (IL)-12 and IL-23 proteins. These proteins are instrumental in managing immune-mediated disorders like psoriasis and inflammatory diseases such as Crohn’s. Teva, in partnership with Alvotech, aims to lead the way in the evolving landscape of biosimilars.
Rich Pipeline and Continued Development
Teva continues to expand its biosimilars footprint with a robust pipeline expected to include more products in the future. This strategy positions the company favorably in terms of competitive advantage and market growth. Recently, Teva launched SELARSDI along with another biosimilar, EPYSQLI, reinforcing its innovative offerings to healthcare providers and patients alike.
In collaboration with Alvotech, two biosimilars have received FDA approval with interchangeable status, signifying a commitment to addressing unmet medical needs through effective biopharmaceutical solutions.
Get to Know SELARSDI™
SELARSDI comes in various formulations, designed for subcutaneous and intravenous administration, ensuring accessibility for different patient needs. These forms include 45 mg/0.5 mL and 90 mg/mL as single-dose prefilled syringes, as well as vials for subcutaneous injection and intravenous infusion.
The Importance of Clinical Collaborations
The partnership between Teva and Alvotech provides a solid foundation for advancing biosimilar development. Alvotech manages the development and manufacturing processes, while Teva's extensive knowledge in commercialization ensures that products effectively reach the market. This synergy enables both companies to focus on delivering high-quality biologics worldwide.
Forward-Looking Strategies in the Biopharmaceutical Sector
In the biopharmaceutical space, Teva's commitment to its Pivot to Growth strategy includes expanding both innovative and biosimilar medicines. This approach not only aims to increase the number of products in their portfolio but also enhances their ability to compete effectively in a rapidly evolving market.
Moreover, ongoing reviews by the FDA for several other biosimilar candidates, including AVT05 and AVT06, indicate that there is significant momentum building behind this segment. These products target existing biologic therapies, potentially offering better access and affordability for patients requiring these treatments.
Enhanced Accessibility for Patients
Overall, the developments surrounding SELARSDI are indicative of a broader trend toward enhancing patient access to biologic treatments through biosimilar products. By making effective therapies more available and affordable, Teva and Alvotech are contributing positively to patient health outcomes.
Frequently Asked Questions
What is SELARSDI™?
SELARSDI™ is a biosimilar to Stelara® (ustekinumab), approved by the FDA for various indications such as plaque psoriasis and Crohn’s disease.
What does FDA’s interchangeability approval mean?
It means that SELARSDI™ can be used as a substitute for Stelara® in treating approved conditions.
What conditions does SELARSDI™ treat?
SELARSDI™ is indicated for moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
How does SELARSDI™ work?
SELARSDI™ targets interleukin-12 and interleukin-23, which are key in inflammatory and immune-mediated diseases.
Who developed SELARSDI™?
SELARSDI™ is developed by Alvotech through a strategic partnership with Teva Pharmaceuticals, focusing on biosimilar medicines.
